Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is a clinical‐stage biotechnology company dedicated to developing allogeneic cell therapies derived from pluripotent stem cells. Headquartered in Carlsbad, California, the company applies a proprietary platform to generate large, well‐characterized banks of differentiated cells intended to address unmet medical needs in ophthalmology, neurology and immuno‐oncology. Lineage’s manufacturing approach leverages standardized, scalable processes designed to maintain product consistency and facilitate broad patient access.
At the core of Lineage’s pipeline is OpRegen, a retinal pigment epithelium (RPE) cell therapy for the treatment of dry age‐related macular degeneration (AMD) with geographic atrophy, currently in late‐stage clinical development. In neurology, the company’s OPC1 candidate employs oligodendrocyte progenitor cells to promote repair and remyelination in acute spinal cord injury patients. In immuno‐oncology, VAC2 is an off‐the‐shelf dendritic cell platform engineered to present tumor antigens and stimulate a targeted T‐cell response against a variety of cancers.
Since its founding as a spin‐out from a publicly traded cell therapy firm in 2013, Lineage has advanced a robust portfolio of both clinical and preclinical programs, including dopaminergic neuron products for Parkinson’s disease and photoreceptor progenitors for retinal dystrophies. The company pursues strategic collaborations and licensing agreements to accelerate development and expand its geographic reach, partnering with academic institutions and industry leaders to validate its cell therapy candidates and support regulatory filings across North America, Europe and Asia.
Under the leadership of Chief Executive Officer Brian M. Culley, Lineage Cell Therapeutics emphasizes rigorous quality control, regulatory engagement and patient safety as it advances toward commercialization. The company’s multidisciplinary management team combines expertise in stem cell biology, regenerative medicine, manufacturing and clinical development, positioning Lineage to deliver transformative therapies to patients worldwide.
